Modality
Vaccine
MOA
EZH2i
Target
CD19
Pathway
Ferroptosis
FTD
Development Pipeline
Preclinical
Feb 2017
→ Apr 2031
PreclinicalCurrent
NCT07943719
1,241 pts·FTD
2019-07→2031-04·Completed
NCT05920859
1,057 pts·FTD
2017-02→2030-06·Recruiting
2,298 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-06-044.2y awayInterim· FTD
2031-04-195.1y awayInterim· FTD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Recruit…
Preclinical
Complet…
Catalysts
Interim
2030-06-04 · 4.2y away
FTD
Interim
2031-04-19 · 5.1y away
FTD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07943719 | Preclinical | FTD | Completed | 1241 | eGFR |
| NCT05920859 | Preclinical | FTD | Recruiting | 1057 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 |